Aguilar, Rebeca Cruz
Salmanton-García, Jon
Carney, Jonathan
Böll, Boris
Kochanek, Matthias
Jazmati, Nathalie
Cornely, Oliver A.
Vehreschild, Maria J. G. T.
Funding for this research was provided by:
Morphochem
Article History
Received: 31 October 2019
Accepted: 11 March 2020
First Online: 24 March 2020
Compliance with ethical standards
:
: MJGTV has received research grants from 3 M, Astellas Pharma, DaVolterra, Gilead Sciences, Glycom, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics; speaker fees from Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, Pfizer and has been a consultant to Alb Fils Kliniken GmbH, Astellas Pharma, DaVolterra, Ferring, MaaT Pharma, Merck/MSD. MK has received speaker fees from Astellas Pharma, Gilead Sciences, Merck/MSD, Pfizer. MRCA has received travel grants from Gilead Sciences and Jazz Pharmaceuticals. BB has received research grants and speaker fees from Celgene, Cytosorbents, Gilead/Kite, MSD, Mundipharma, Johnson & Johnson and Takeda. JSG had no conflicts of interest. JC had no conflicts of interest. NJ has received a research grant from DaVolterra. OAC is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Scynexis, Seres Therapeutics, Tetraphase, and Vical.